• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases > DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases > Page 2

DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases

The partnership brings together DNDi’s global expertise in needs driven drug development and Dubai Health’s integrated academic health system to support research and capacity building across priority global health areas

Home > Press releases > DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases > Page 2

DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases

The partnership brings together DNDi’s global expertise in needs driven drug development and Dubai Health’s integrated academic health system to support research and capacity building across priority global health areas

Dubai, UAE — 10 Feb 2026

Dubai Health has signed a Memorandum of Understanding (MoU) with the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) at World Health Expo Dubai (WHX).

The agreement was signed by Dr Hanan Al Suwaidi, Deputy CEO and Chief Academic Officer of Dubai Health and Provost of Mohammed Bin Rashid University of Medicine and Health Sciences, and Dr Luis Pizarro, Executive Director of the Drugs for Neglected Diseases initiative (DNDi).

Dr Hanan Al Suwaidi, Deputy CEO and Chief Academic Officer of Dubai Health and Provost of Mohammed Bin Rashid University of Medicine and Health Sciences, and Dr Luis Pizarro, Executive Director of the Drugs for Neglected Diseases initiative (DNDi)

The partnership establishes a framework for collaboration in medical education, research, and clinical training, with a shared goal of improving health outcomes for underserved populations affected by neglected infectious diseases. It brings together DNDi’s global expertise in needs‑driven drug discovery and development and Dubai Health’s integrated academic health system to support research and capacity‑building across priority global health areas.

Under the agreement, students from Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) will take part in DNDi‑led programmes, including fieldwork and clinical research activities in Africa and Asia. These programmes provide hands‑on exposure to patients affected by neglected diseases and to the full spectrum of drug discovery, development and public health delivery. DNDi experts will also contribute to MBRU academic programmes, supporting two‑way academic and professional exchange.

The collaboration will begin with joint research scoping to identify priority projects. It will involve active faculty engagement through guest lectures, curriculum development, student co‑supervision, joint grant applications, and collaborative research publications.

The partnership will also encompass collaboration in drug discovery, clinical trials, regulatory science, and public health policy, with a particular focus on viral diseases, pandemic preparedness, and fungal infections. In addition, it will support joint initiatives in the application of artificial intelligence to health research, as well as the co‑organization of scientific conferences and workshops and the dissemination of knowledge on key global health challenges.

Dr Luis Pizarro, said: ‘Neglected diseases disproportionately affect the world’s most vulnerable populations and are often overlooked by traditional research models. Through this partnership with Dubai Health, we aim to advance scientific progress while helping train the next generation of global health leaders to deliver more equitable health solutions.‘

Dr Hanan AlSuwaidi, said: ‘This partnership represents a meaningful step forward in how we prepare our students and researchers to engage with the world’s most pressing and complex health challenges. By partnering with DNDi, we are giving our learners direct access to real-world drug development, clinical research, and global health practice. It reflects our commitment to advancing health for humanity by ensuring that innovation, learning, and discovery are driven by purpose and real-world impact.‘

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected populations. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, river blindness, lymphatic filariasis, female genital schistosomiasis, mycetoma, dengue, paediatric HIV, cryptococcal meningitis, and hepatitis C. Its research priorities include children’s health; gender equity and gender-responsive R&D; and diseases impacted by climate change. Since its creation in 2003, DNDi has collaborated with public and private partners worldwide to deliver thirteen new treatments for six deadly diseases, saving millions of lives. dndi.org

About Dubai Health

Dubai Health, the first integrated academic health system in Dubai, was established to elevate the standard of care and to advance health for humanity. Dubai Health is comprised of 6 hospitals, 26 ambulatory health centers, 21 medical fitness centers, Mohammed Bin Rashid University of Medicine and Health Sciences, and Al Jalila Foundation. Together, Dubai Health serves patients through the integration of care, learning, discovery, and giving. A workforce of over 11,000 collaborates across multidisciplinary teams to put the patient first.

Media contact

media@dndi.org

Photo credit: Lameck Ododo-DNDi

Partnership Africa Asia

Read, watch, share

Loading...
Statements
23 Jan 2026

DNDi’s briefing note for 158th Session of the WHO Executive Board

News
16 Dec 2025

DNDi 2025 in Review

News
8 Dec 2025

DNDi statement on COP30: Advancing health in the climate agenda

News
4 Dec 2025

Dr Javid Abdelmoneim, Datuk Dr Mahathar bin Abd Wahab, Dr Taruna Madan, Violet Naanyu, and Dr Mario Santos Moreira join the Board of Directors at DNDi

Press releases
27 Nov 2025

International seminar explores the development of treatments for dengue for populations not covered by vaccines

News
26 Nov 2025

DNDi statement on the approval of the Instituto Butantan’s dengue vaccine and the need for a dengue treatment

Dr Pauline Williams
Videos
24 Nov 2025

Interview with Dr Pauline Williams, new DNDi Scientific Advisory Committee (SAC) Chair

Financial Times logo
Viewpoints
20 Nov 2025

Neglecting infectious diseases is a market failure

Financial Times
VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license